GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Vaccine Inc (SZSE:301207) » Definitions » Debt-to-Equity

Hualan Biological Vaccine (SZSE:301207) Debt-to-Equity : 0.05 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Hualan Biological Vaccine Debt-to-Equity?

Hualan Biological Vaccine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥300 Mil. Hualan Biological Vaccine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥0 Mil. Hualan Biological Vaccine's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥6,307 Mil. Hualan Biological Vaccine's debt to equity for the quarter that ended in Mar. 2024 was 0.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hualan Biological Vaccine's Debt-to-Equity or its related term are showing as below:

SZSE:301207' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05   Med: 0.07   Max: 0.3
Current: 0.05

During the past 7 years, the highest Debt-to-Equity Ratio of Hualan Biological Vaccine was 0.30. The lowest was 0.05. And the median was 0.07.

SZSE:301207's Debt-to-Equity is ranked better than
73.09% of 1074 companies
in the Biotechnology industry
Industry Median: 0.145 vs SZSE:301207: 0.05

Hualan Biological Vaccine Debt-to-Equity Historical Data

The historical data trend for Hualan Biological Vaccine's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Vaccine Debt-to-Equity Chart

Hualan Biological Vaccine Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial - 0.09 0.18 0.06 0.05

Hualan Biological Vaccine Quarterly Data
Dec17 Dec18 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.06 0.05 0.05 0.05

Competitive Comparison of Hualan Biological Vaccine's Debt-to-Equity

For the Biotechnology subindustry, Hualan Biological Vaccine's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hualan Biological Vaccine's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Vaccine's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hualan Biological Vaccine's Debt-to-Equity falls into.



Hualan Biological Vaccine Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hualan Biological Vaccine's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Hualan Biological Vaccine's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hualan Biological Vaccine  (SZSE:301207) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Hualan Biological Vaccine Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hualan Biological Vaccine's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Vaccine (SZSE:301207) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, No. 1, Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Website
Hualan Biological Vaccine Inc is engaged in Research, development, production and sales of human vaccines.

Hualan Biological Vaccine (SZSE:301207) Headlines

No Headlines